Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. February 16, 2016 ARTICLE CITATION DOI: 10.1200/JCO.2015.64.9970 Journal of Clinical Oncology - published online before print February 16, 2016 PMID: 26884583 Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma Nicole C. SmitsxNicole C. SmitsSearch for articles by this author , Charles L. SentmanxCharles L. SentmanSearch for articles by this author Show More Geisel School of Medicine at Dartmouth, Lebanon, NH https://doi.org/10.1200/JCO.2015.64.9970 First Page Full Text PDF Figures and Tables © 2016 by American Society of Clinical Oncology Companion Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
No takes yet. Share an insight, caveat, or question.
Smits et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: